Usefulness of extended‐release topiramate in patients with epilepsy: A two‐year retention study

2021 ◽  
Author(s):  
Hyemi Lee ◽  
Dong Wook Kim
Keyword(s):  
Extended Release ◽  
Patients With Epilepsy ◽  
Retention Study

Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: A double-blind, randomized, placebo-controlled trial

Epilepsia ◽  
2009 ◽  
Vol 50 (3) ◽  
pp. 406-414 ◽  
Author(s):  
Jukka Peltola ◽  
Christo Coetzee ◽  
Fiacro Jiménez ◽  
Tetyana Litovchenko ◽  
Sridharan Ramaratnam ◽  
...  
Keyword(s):  
Extended Release ◽  
Controlled Trial ◽  
Adjunctive Treatment ◽  
Double Blind ◽  
Once Daily ◽  
Patients With Epilepsy

scholarly journals Efficacy, safety, and retention rate of extended-release divalproex versus conventional delayed-release divalproex: A protocol for systematic review and meta-analysis

2021 ◽  
Author(s):  
Chen qi Zhang ◽  
◽  
Xueyang Bai ◽  
Yong Wan ◽  
Hongyan Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Extended Release ◽  
Retention Rate ◽  
Meta Analysis ◽  
Small Sample ◽  
Safety And Efficacy ◽  
Delayed Release ◽  
Review Question ◽  
Different Populations ◽  
Patients With Epilepsy

Review question / Objective: We aim to systematically examine and compare the efficacy, safety and retention rate of ER divalproex (VPA-ER) and conventional DR divalproex (VPA-DR) on patients with epilepsy. Condition being studied: To our knowledge, comparison and conversion studies about VPA-ER and conventional VPA-DR are lacked. Small-sample studies analyzing the safety and efficacy of VPA-ER in different populations remain controversial. Therefore, this study aims to systematically review the safety, efficacy and retention rate of VPA-ER and VPA-DR by meta-analysis.

scholarly journals Successful bilateral electroconvulsive therapy in a patient with a seizure disorder taking levetiracetam, lorazepam, and zonisamide: A case report

2021 ◽  
Vol 11 (1) ◽  
pp. 23-26
Author(s):  
Ian R. McGrane ◽  
Rachel E. Tenison ◽  
Dana M. Bimler ◽  
Robert C. Munjal ◽  
Jason R. Molinaro
Keyword(s):  
Bipolar Disorder ◽  
Electroconvulsive Therapy ◽  
Extended Release ◽  
Medication Management ◽  
Immediate Release ◽  
Seizure Threshold ◽  
Treatment Resistant ◽  
Evening Dose ◽  
Patients With Epilepsy ◽  
Higher Doses

Abstract Electroconvulsive therapy (ECT) may be considered for treatment of severe, treatment-resistant, and emergent depression associated with MDD or bipolar disorder. Patients with epilepsy usually take medications that raise the seizure threshold, which poses challenges during ECT. We report a 66-year-old male with epilepsy taking levetiracetam extended-release (XR), lorazepam, and zonisamide requiring ECT for severe MDD. After literature review, the XR form of levetiracetam was changed to higher doses of the immediate-release (IR) formulation, and zonisamide was discontinued 2 days prior to ECT in the hospital and was resumed when the patient underwent outpatient continuation ECT. The patient was treated to remission after receiving 8 acute bilateral ECT treatments before being transitioned to continuation ECT. We provide a brief review of medication management of antiepileptic drugs and other medications that increase the seizure threshold during ECT. To our knowledge, this is the first reported case describing the management of levetiracetam, lorazepam, and zonisamide concomitantly during ECT. Our case suggests that utilizing the IR formulation of levetiracetam, administering the evening dose early the day prior to the procedure, and temporarily discontinuing zonisamide prior to bilateral ECT is effective for the treatment of severe MDD while maintaining seizure prophylaxis.

Every-12-hour administration of extended-release divalproex in patients with epilepsy: Impact on plasma valproic acid concentrations

2006 ◽  
Vol 8 (2) ◽  
pp. 391-396 ◽  
Author(s):  
Ronald C. Reed ◽  
Sandeep Dutta ◽  
John H. Cavanaugh ◽  
Charles Locke ◽  
G. Richard Granneman
Keyword(s):  
Valproic Acid ◽  
Extended Release ◽  
Patients With Epilepsy

scholarly journals Pharmacokinetic Evaluation of Twice-Daily Extended-Release Carbamazepine (CBZ) and Four-Times-Daily Immediate-Release CBZ in Patients with Epilepsy

Epilepsia ◽  
1998 ◽  
Vol 39 (3) ◽  
pp. 274-279 ◽  
Author(s):  
William R. Garnett ◽  
Benjamin Levy ◽  
Angus M. McLean ◽  
Yuxin Zhang ◽  
Richard A. Couch ◽  
...  
Keyword(s):  
Extended Release ◽  
Immediate Release ◽  
Patients With Epilepsy ◽  
Pharmacokinetic Evaluation

1271: Effects of Darifenacin and Extended-Release Oxybutynin on Memory in Older Subjects

2006 ◽  
Vol 175 (4S) ◽  
pp. 409-409 ◽  
Author(s):  
Gary Kay ◽  
Thomas Crook ◽  
Ludmyla Rekeda ◽  
Raul Lima
Keyword(s):  
Extended Release ◽  
Older Subjects
Sign in / Sign up

Export Citation Format

Share Document